Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 12,520 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Sutured Wounds
Interventions: Hydrogen peroxide, Saline; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Anemia
Interventions: Epoetin alfa 3 times weekly /once weekly, Epoetin alfa once weekly, Epoetin alfa once every two weeks; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 61
States / cities: Glendale, Arizona • Tempe, Arizona • Chula Vista, California + 58 more

Conditions: Healthy, Hepatic Insufficiency
Interventions: LY3437943; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Chandler, Arizona • DeLand, Florida • Miami, Florida + 1 more

Conditions: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Plecanatide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,054 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 155
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 142 more

Conditions: Bipolar Disorder
Interventions: integrative behavior couples therapy; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 64 Years
Enrollment: 40 participants
Timeline: Started 2005
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer, Urothelial Carcinoma (UC), Cholangiocarcinoma, Mesothelioma, Gallbladder Cancer, Ovarian Cancer
Interventions: MDX2001; Drug
Lead sponsor: ModeX Therapeutics, An OPKO Health Company; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Lung Cancer
Interventions: cisplatin, etoposide, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 80 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2010
U.S. locations: 242
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 189 more

Conditions: Gout
Interventions: PRX-115, Methotrexate (MTX), PRX-115 placebo, Placebo-Methotrexate; Biological · Drug · Other
Lead sponsor: Protalix; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 26
States / cities: Glendale, Arizona • Little Rock, Arkansas • Anaheim, California + 20 more

Conditions: Immune Thrombocytopenia
Interventions: Avatrombopag Oral Tablet; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Whittier, California • Washington D.C., District of Columbia + 17 more

Conditions: Metastatic Carcinoma
Interventions: Radiation Therapy; Radiation
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Idiopathic Urticaria
Interventions: Placebo, Omalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 36
States / cities: La Jolla, California • Los Angeles, California • Redwood City, California + 31 more

Conditions: Colitis, Ulcerative
Interventions: Trichuris suis ova (TSO), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Palo Alto, California • New Haven, Connecticut • Miami, Florida + 13 more

Conditions: HIV Infections
Interventions: SEPA+PrEP Women; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Multiple Myeloma
Interventions: Elranatamab (PF-06863135); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 33
States / cities: Los Angeles, California • Orange, California • Miami, Florida + 16 more

Conditions: Gout
Interventions: SEL-110, SEL-212, SEL-037; Drug · Biological
Lead sponsor: Selecta Biosciences, Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 3 more

Conditions: Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions: Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo; Biological
Lead sponsor: University of Miami; Other
Eligibility: 21 Years to 90 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Acne Vulgaris
Interventions: Olumacostat Glasaretil Gel, 5.0%; Drug
Lead sponsor: Dermira, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 748 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 73
States / cities: Guntersville, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Hemophilia A
Interventions: Emicizumab; Biological
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years and older
U.S. locations: 14
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 11 more

Conditions: Spinal Cord Injury
Interventions: rTMS, Sham rTMS, Training, Motor Task; Device · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Hines, Illinois • Pittsburgh, Pennsylvania

Conditions: Coronavirus Disease 2019
Interventions: Pentarlandir™ UPPTA, Placebo; Drug
Lead sponsor: SyneuRx International (Taiwan) Corp; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Cullman, Alabama • Gilbert, Arizona • Bradenton, Florida + 6 more

Conditions: Multiple Myeloma
Interventions: Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 28
States / cities: Alabaster, Alabama • Surprise, Arizona • Berkeley, California + 25 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: Adalimumab, Lisinopril, losartan, and atorvastatin, galactose; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 1 Year to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 17
States / cities: Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more

Conditions: Infections, Papillomavirus
Interventions: GSK Biological's HPV vaccine GSK580299 (Cervarix™); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 346 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 39
States / cities: San Diego, California • San Francisco, California • Denver, Colorado + 34 more

Conditions: Papillomavirus Infections
Interventions: 9vHPV Vaccine, Placebo (Saline for Injection); Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 20 Years to 45 Years · Male only
Enrollment: 6,033 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Northridge, California • Rialto, California • Simi Valley, California + 28 more

Search by objective public record fields.

A Comparison Study of the Tensile Strength of Sutures Used in Dermatologic Surgery on the Day of Suture Removal, Following Wound Care With Two Different Products

An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney Disease

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)

Family Workshops for Bipolar Disorder

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

SEPA+PrEP-Women Pilot Trial for HIV Prevention Among Women at Risk for HIV

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors

Improving Motor Function After Spinal Cord Injury

Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)